Recent Price Movement and Market Context
On 18 Dec 2025, Biofil Chemicals & Pharmaceuticals touched its lowest price point in the last year at Rs.32.59. This level represents a notable drop from its 52-week high of Rs.67.50, indicating a decline of more than 50% over the period. The stock has underperformed its sector peers, with a day change of -1.83%, which is 0.89% below the Pharmaceuticals & Biotechnology sector’s performance on the same day.
Over the last three trading days, the stock has recorded a cumulative return of -5.06%, signalling a persistent downward trend. This movement contrasts with the broader market, where the Sensex opened flat and traded marginally lower by 0.02%, standing at 84,541.54 points. The Sensex remains close to its 52-week high of 86,159.02, just 1.91% away, and is trading above its 50-day and 200-day moving averages, reflecting a generally bullish market environment.
Technical Indicators and Moving Averages
Biofil Chemicals & Pharmaceuticals is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a sustained weakness in the stock’s price momentum. The gap between the current price and these moving averages highlights the extent of the stock’s decline relative to its recent trading history.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Long-Term Performance and Comparative Analysis
Examining the one-year performance, Biofil Chemicals & Pharmaceuticals has recorded a return of -45.60%, a stark contrast to the Sensex’s positive return of 5.44% over the same period. This divergence underscores the stock’s consistent underperformance relative to the broader market benchmark. Additionally, the stock has lagged behind the BSE500 index in each of the last three annual periods, reflecting a persistent trend of relative weakness.
The company’s 52-week high of Rs.67.50 further emphasises the scale of the decline, with the current price representing less than half of that peak value. This performance gap highlights the challenges faced by the company within its sector and the broader market context.
Financial Metrics and Profitability Indicators
Biofil Chemicals & Pharmaceuticals’ financial data over recent years reveals several areas of concern. The company’s operating profits have shown a compound annual growth rate (CAGR) of -24.21% over the last five years, indicating a contraction in core earnings. This trend has implications for the company’s ability to generate sustainable profits from its operations.
Debt servicing capacity is another area of note, with the company’s average EBIT to interest ratio standing at 0.66. This figure suggests limited coverage of interest expenses by earnings before interest and tax, pointing to potential financial strain in managing debt obligations.
Return on equity (ROE) averages at 5.27%, signalling modest profitability relative to shareholders’ funds. This level of ROE is comparatively low within the Pharmaceuticals & Biotechnology sector, where higher returns are often expected given the capital intensity and growth prospects.
Recent Operational Highlights
Despite the overall downward trend in stock price, Biofil Chemicals & Pharmaceuticals reported positive developments in its latest six-month financial results. Net sales for this period stood at Rs.19.97 crores, reflecting a growth rate of 84.06%. Profit after tax (PAT) also showed an increase, reaching Rs.2.49 crores.
The company’s return on equity for the latest period was recorded at 13.4%, accompanied by a price-to-book value of 2.6. These figures suggest an attractive valuation relative to some peers, with the stock trading at a discount compared to average historical valuations within the sector.
Holding Biofil Chemicals & Pharmaceuticals from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Shareholding and Market Capitalisation
The majority of Biofil Chemicals & Pharmaceuticals’ shares are held by non-institutional investors, indicating a shareholder base dominated by retail or private investors. The company’s market capitalisation grade is rated at 4, reflecting its size and market presence within the Pharmaceuticals & Biotechnology sector.
While the stock’s recent performance has been subdued, the company’s financial results and valuation metrics provide a nuanced picture of its current standing in the market.
Summary of Current Position
Biofil Chemicals & Pharmaceuticals’ stock has reached a significant low point at Rs.32.59, marking a 52-week trough amid a broader market that remains relatively stable. The stock’s technical indicators, long-term financial metrics, and comparative performance against benchmarks highlight ongoing challenges. However, recent sales and profit figures indicate areas where the company has shown growth, albeit within a context of overall price weakness.
Investors and market participants observing Biofil Chemicals & Pharmaceuticals will note the contrast between the stock’s price trajectory and the company’s operational data, which includes both areas of concern and pockets of positive development.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Claim Your Free Year →
